FUDAN ZHANGJIANG (688505.SH): The first subject enrolled in Phase II clinical trial in the United States for using Heimbofen injections to treat fresh red birthmarks.

FUDANZHANGJIANG (688505.SH) announced that the Phase II clinical trial of the F0026 project, a Hemoporfin injection for treating port-wine stains developed by the company, has recently successfully enrolled its first subject in the United States. Hemoporfin is the world's first photosensitizer drug for the treatment of port-wine stains, which combines new drug targets, new compounds, and new indications into one drug. As a second-generation photosensitizer, Hemoporfin has the characteristics of a stable compound structure and low phototoxicity. Its use in the treatment of port-wine stains has been included in the ninth edition of the textbook "Dermatology" by the People's Medical Publishing House.